These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34615406)

  • 21. CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Mohabati D; Hoyng CB; Yzer S; Boon CJF
    Retina; 2020 Sep; 40(9):1742-1750. PubMed ID: 31815880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
    Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial.
    Willcox A; Culliford L; Ellis L; Rogers CA; Cree A; Chakravarthy U; Ennis S; Behar-Cohen F; Reeves BC; Sivaprasad S; Lotery A
    Eye (Lond); 2019 Feb; 33(2):295-303. PubMed ID: 30194380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
    Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.
    Hwang S; Kang SW; Kim SJ; Jang JW; Kim KT
    Retina; 2019 Jun; 39(6):1117-1124. PubMed ID: 29517581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystoid macular degeneration in chronic central serous chorioretinopathy.
    Iida T; Yannuzzi LA; Spaide RF; Borodoker N; Carvalho CA; Negrao S
    Retina; 2003 Feb; 23(1):1-7; quiz 137-8. PubMed ID: 12652224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functionality of retinal vessels in central serous retinopathy: A comparison between eplerenone and photodynamic therapy.
    Tombolini B; Battista M; Sacconi R; Servillo A; Camisa L; Bandello F; Querques G
    Eur J Ophthalmol; 2023 May; 33(3):1443-1451. PubMed ID: 36503297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foveal and Extrafoveal Effects of Half-Dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Cohort Study.
    Pinto C; Sousa K; Oliveira E; Mendonça L; Gentil R; Queirós L; Falcão M
    Semin Ophthalmol; 2022 Feb; 37(2):153-157. PubMed ID: 34027797
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial.
    van Rijssen TJ; van Dijk EHC; Tsonaka R; Feenstra HMA; Dijkman G; Peters PJH; Diederen RMH; Hoyng CB; Schlingemann RO; Boon CJF
    Am J Ophthalmol; 2022 Jan; 233():101-110. PubMed ID: 34214454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reply to comment on: Optical coherence tomography angiography in central serous chorioretinopathy treated with oral eplerenone and half-fluence photodynamic therapy: A comparative study.
    Clemente L; Cennamo G; Montorio D; Fossataro F; Passaro ML; Costagliola C
    Eur J Ophthalmol; 2024 May; 34(3):NP132-NP133. PubMed ID: 37899584
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of mineralocorticoid receptor antagonist for central serous chorioretinopathy: a meta-analysis.
    Zhang B; Chou Y; Zhao X; Yang J; Chen Y
    Int Ophthalmol; 2020 Nov; 40(11):2957-2967. PubMed ID: 32632615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.
    Park YJ; Kim YK; Park KH; Woo SJ
    Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.
    Russo A; Turano R; Morescalchi F; Gambicorti E; Cancarini A; Duse S; Costagliola C; Semeraro F
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1141-1148. PubMed ID: 28283732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C
    Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of Outcome During Eplerenone Therapy in Chronic Central Serous Chorioretinopathy:A Prospective, Open-Label Pilot Clinical Study.
    Rajesh B; Agrawal H; Peguda HK; Chhablani J
    Ophthalmic Surg Lasers Imaging Retina; 2018 Jul; 49(7):479-486. PubMed ID: 30021034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.